MA49886A - Anticorps anti-par2 et leurs utilisations - Google Patents
Anticorps anti-par2 et leurs utilisationsInfo
- Publication number
- MA49886A MA49886A MA049886A MA49886A MA49886A MA 49886 A MA49886 A MA 49886A MA 049886 A MA049886 A MA 049886A MA 49886 A MA49886 A MA 49886A MA 49886 A MA49886 A MA 49886A
- Authority
- MA
- Morocco
- Prior art keywords
- par2 antibodies
- par2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49886A true MA49886A (fr) | 2020-06-24 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049886A MA49886A (fr) | 2017-03-16 | 2018-03-16 | Anticorps anti-par2 et leurs utilisations |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10836822B2 (enExample) |
| EP (1) | EP3596125B1 (enExample) |
| JP (3) | JP7222901B2 (enExample) |
| KR (1) | KR102711884B1 (enExample) |
| CN (1) | CN110446720B (enExample) |
| AU (3) | AU2018235031B2 (enExample) |
| BR (1) | BR112019018752A2 (enExample) |
| CA (1) | CA3055251A1 (enExample) |
| CL (1) | CL2019002626A1 (enExample) |
| CO (1) | CO2019010975A2 (enExample) |
| CR (1) | CR20190417A (enExample) |
| IL (1) | IL269134B2 (enExample) |
| MA (1) | MA49886A (enExample) |
| MX (1) | MX2019010802A (enExample) |
| NZ (1) | NZ757915A (enExample) |
| PH (1) | PH12019502087A1 (enExample) |
| PT (1) | PT3596125T (enExample) |
| SG (1) | SG11201908056QA (enExample) |
| TW (1) | TWI788332B (enExample) |
| UA (1) | UA125757C2 (enExample) |
| WO (1) | WO2018167322A1 (enExample) |
| ZA (1) | ZA201906004B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP4231014A3 (en) | 2010-11-30 | 2024-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| JP6174782B2 (ja) | 2014-12-19 | 2017-08-02 | 中外製薬株式会社 | 抗ｃ５抗体および使用方法 |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| EP3596125B1 (en) * | 2017-03-16 | 2025-11-19 | MedImmune Limited | Anti-par2 antibodies and uses thereof |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| JP2023538379A (ja) | 2020-08-18 | 2023-09-07 | セファロン エルエルシー | 抗ｐａｒ－２抗体及びそれらの使用方法 |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| EP4655068A1 (en) | 2023-01-25 | 2025-12-03 | MedImmune Limited | Migraine therapy |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20070053911A1 (en) * | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CA2586344C (en) * | 2004-11-04 | 2013-05-28 | New England Medical Center Hospitals, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) * | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| JP2011530515A (ja) | 2008-08-05 | 2011-12-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用 |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| AU2011225716A1 (en) * | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
| WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| KR20150041662A (ko) * | 2012-08-13 | 2015-04-16 | 리제너론 파아마슈티컬스, 인크. | Ｐｈ-의존적 결합 특성을 갖는 항-ｐｃｓｋ9 항체 |
| US10183994B2 (en) * | 2014-06-30 | 2019-01-22 | Merck Patent Gmbh | Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence |
| EP3596125B1 (en) * | 2017-03-16 | 2025-11-19 | MedImmune Limited | Anti-par2 antibodies and uses thereof |
-
2018
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/en active Active
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en not_active Ceased
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1020I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| EP3625263A4 (en) | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF | |
| EP3383916A4 (en) | Anti-cd73 antibodies and uses thereof | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| EP3891183A4 (en) | ANTI-CLAUDIN ANTIBODIES AND USES THEREOF | |
| EP3389702A4 (en) | ANTI-LAG-3 ANTIBODIES AND USES THEREOF | |
| MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
| EP3661965A4 (en) | ANTI-CD47 ANTIBODIES AND USES THEREOF | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| EP3426288A4 (en) | ANTI-PACAP ANTIBODIES AND USES THEREOF | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3918323A4 (en) | ANTI-GAL3 ANTIBODIES AND USES THEREOF | |
| EP3328895A4 (en) | ANTI-PD-1 ANTIBODIES AND USES THEREOF | |
| EP3645563A4 (en) | ANTI-FAM19A5 ANTIBODIES AND USES THEREOF | |
| EP3283517A4 (en) | ANTI-PACAP ANTIBODIES AND USES THEREOF | |
| EP3383904A4 (en) | CTLA-4 ANTIBODIES AND USES THEREOF | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3661555A4 (en) | SPECIFIC ANTIBODIES AND USES THEREOF |